Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome

BACKGROUND AND OBJECTIVE: Alemtuzumab (Campath(®)) is used to prevent graft-versus-host disease and graft failure following pediatric allogeneic hematopoietic cell transplantation. The main toxicity includes delayed immune reconstitution, subsequent viral reactivations, and leukemia relapse. Exposur...

Descripción completa

Detalles Bibliográficos
Autores principales: Admiraal, Rick, Jol-van der Zijde, Cornelia M., Furtado Silva, Juliana M., Knibbe, Catherijne A. J., Lankester, Arjan C., Boelens, Jaap Jan, Hale, Goeff, Etuk, Aniekan, Wilson, Melanie, Adams, Stuart, Veys, Paul, van Kesteren, Charlotte, Bredius, Robbert G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885503/
https://www.ncbi.nlm.nih.gov/pubmed/31131436
http://dx.doi.org/10.1007/s40262-019-00782-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885503/
https://www.ncbi.nlm.nih.gov/pubmed/31131436
http://dx.doi.org/10.1007/s40262-019-00782-0

Ejemplares similares